The UK Health Security Agency (UKHSA) has unveiled its preliminary risk analysis of the SARS-CoV-2 variant BA.2.86, a strain first detected in the UK on 18 August. International traces of this variant have been found in countries including Israel, Denmark, and the US. Distinctively genomically distant from its likely progenitor, BA.2, and the prevalent XBB-derived […]
Firebrick Pharma, an ASX-listed pharmaceutical company, announced that it has successfully enrolled 160 subjects in the confirmatory phase 3 clinical trial of Nasodine Nasal Spray as a potential treatment for the common cold. This enrollment figure represents approximately 82% of the final recruitment target for the trial. The clinical trial, which commenced in 2022, aims […]
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the US Food and Drug Administration (FDA) to treat adult patients with mild-to-moderate COVID-19 who are at a high risk of hospitalization or death. PAXLOVID has been available in the US since December 2021 under Emergency Use Authorization […]
AstraZeneca has signed a licensing deal with RQ Biotechnology (RQ Bio) to gain access to a portfolio of early-stage monoclonal antibodies (mAbs) targeted against Covid-19 causing SARS-CoV-2 virus. As per the terms, AstraZeneca has acquired an exclusive global licence for developing, manufacturing, and commercializing mAbs against SARS-CoV-2. Iskra Reic — AstraZeneca Vaccines and Immune Therapies […]
AstraZeneca said that its antibody combination Evusheld (tixagevimab co-packaged with cilgavimab) has been authorized by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the prevention of Covid-19 in Britain. Evusheld has been approved to be used in adults who are not presently infected with (or know exposure to) the Covid-19 virus and are […]
Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment. Pfizer’s oral Covid-19 treatment is made up of PAXLOVID (nirmatrelvir), which inhibits a SARS-CoV-2 protein to prevent the SARSCoV-2 virus from replicating and ritonavir, which slows down the breakdown of […]
Sorrento Therapeutics has acquired a majority stake in Zhengzhou Fortune Bioscience (Zhengzhou FortuneBio), a Chinese diagnostic manufacturer, for an undisclosed price. According to Sorrento Therapeutics, the acquisition is in response to drastic increasing demands around the world and planned product build-up expecting possible additional approvals for its COVISTIX Covid-19 virus rapid antigen detection test. Zhengzhou […]
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of mild-to-moderate Covid-19. According to Lilly, bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2, which has also shown capability to neutralize against the Omicron […]
Glenmark Pharmaceuticals and Canadian pharma company SaNOtize Research & Development Corp. have launched the latter’s Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adults with Covid-19, who have a high risk of disease progression Earlier, Glenmark Pharmaceuticals had secured manufacturing and marketing approval from the Drugs Controller General […]
Celltrion Group (Celltrion Healthcare), a South Korean pharma company, has submitted an investigational new drug (IND) application to carry out a global phase 3 clinical trial of an inhaled Covid-19 antibody cocktail therapy made up of regdanvimab (CT-P59) and CT-P63. The late-stage clinical trial will assess the efficacy and safety of the cocktail therapy in […]